Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$274K Buy
2,940
+396
+16% +$35.1K ﹤0.01% 1323
2025
Q4
$204K Sell
2,544
-64
-2% -$5.36K ﹤0.01% 1382
2025
Q3
$255K Buy
+2,608
New +$210K ﹤0.01% 1246
2024
Q4
Sell
-2,138
Closed -$224K 1444
2024
Q3
$224K Buy
2,138
+77
+4% +$9.01K ﹤0.01% 1197
2024
Q2
$293K Buy
2,061
+92
+5% +$10.6K ﹤0.01% 1067
2024
Q1
$220K Sell
1,969
-11
-0.6% -$1.31K ﹤0.01% 1158
2023
Q4
$257K Buy
1,980
+64
+3% +$8.82K ﹤0.01% 1096
2023
Q3
$312K Hold
1,916
﹤0.01% 1027
2023
Q2
$351K Buy
1,916
+27
+1% +$3.89K ﹤0.01% 1006
2023
Q1
$252K Buy
+1,889
New +$222K ﹤0.01% 1084

Other funds holding ACLS

Xponance's ACLS Position: Q1 2026 in Review

Xponance increased its Axcelis (ACLS) stake by 16% in Q1 2026, buying an estimated $35.1K and bringing the position to 2,940 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

Xponance first reported a position in ACLS in Q1 2023 and has held it in 10 quarters since. The position peaked at $351K in Q2 2023. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • Xponance held 2,940 shares of Axcelis worth $274K as of Q1 2026.
  • Xponance bought 396 Axcelis shares in Q1 2026, an estimated $35.1K.
  • Axcelis made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1323 holding.
  • Xponance first reported a position in Axcelis in Q1 2023 and has held it in 10 quarters since.
  • Xponance's Axcelis position peaked at $351K in Q2 2023.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.